Navigation

Personal tools

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit https://cc.nih.gov/.

Updates regarding government operating status and resumption of normal operations can be found at https://USA.gov/.

You are here: Home / Protocols / EDRN Biomarker Reference Lab: Pacific Northwest National Laboratory
Team Project

EDRN Biomarker Reference Lab: Pacific Northwest National Laboratory

231

No coordinating investigator defined.

Other, Specify

The purpose of this project is to develop antibody microarrays incorporating three major improvements compared to previous antibody microarray platforms, and to produce and disseminate these antibody microarray technologies for the Early Detection Research Network (EDRN) and the research community focusing on early detection, and risk assessment of cancer.

Stage I: A feasibility study – comparing a limited number (5) of available scFv library derived antibodies (in a number of antibody formats such as scFv, Fab and IgG) and commercially available monoclonal antibodies directed at the same cancer-associated antigens on the same slide with appropriate controls. This will involve identification, development, and production, of 20 monoclonal antibody pairs specific for 5 antigens with subsequent utilization demonstrated in a micro ELISA assay. The antibody pairs are represented by one detection antibody and 4 capture antibodies derived as affinity matured subclones directed against the same epitope. The capture antibodies will have affinities ranging from 100 nM to 100 pM. Stage II: Extension of the phase I study to ~50 antigens and controls chosen on the basis of potential as cancer biomarkers. In this stage PNNL will: (a) train selected EDRN investigators in the use of the microarray platform, and (b) print a large number of microarrays (1500 slides) for analytical and clinical validation studies.

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement 10/23/2017

Three new FOAs on the Human Tumor Atlas and associated with the Cancer Moonshot Initiative have been released. Please click here for more information.

10th Science Workshop
Thank you to everyone who made the 32nd EDRN Steering Committee meeting a success. The next event is the 10th EDRN Scientific Workshop from March 6-8, 2018 in Bethesda, MD. Click to view the flyer; click to visit the registration page.
EDRN Founder Honored

Dr. Sudhir Srivastava was honored with the Distinguished Service Award from the American Pancreatic Association at the group's annual meeting this year, for his outstanding commitment to pancreatology.